Please login to the form below

Not currently logged in
Email:
Password:

Hisun

This page shows the latest Hisun news and features for those working in and with pharma, biotech and healthcare.

Pfizer cuts 2013 forecast after weak first quarter

Pfizer cuts 2013 forecast after weak first quarter

of $490m from the transfer of certain product rights to its China-based joint venture with Hisun.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    Watson continues to extend its women's health franchise. Picking up on several of last year's deal trends, Zhejiang Hisun reported the closure of an exclusive option to access ... So the deployment of an option excluding third party access in this case

  • Biosimilars in China Biosimilars in China

    Several joint venture deals between MNCs and Chinese players have been sealed recently: Hisun with Pfizer, Simcere with Merck and Fosun with Lonza.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics